openPR Logo
Press release

U.S. Contraceptives Drugs And Devices Market, By Product Type - Insights, Opportunity Analysis, and Industry Forecast till 2024

10-13-2017 03:03 PM CET | Health & Medicine

Press release from: U.S. Contraceptives Drugs And Devices Market

U.S. Contraceptives Drugs And Devices Market, By Product Type -

Contraceptive Drugs and Devices – Choice to Conceive, Not Concede

As per stats released by Guttmacher Institute, there were around 61 million women in the U.S. in the childbearing age group (15-44 years) in 2014. Around 10% of these women do not use any contraceptive method. The UN estimates (2015) that unmet need for contraceptives in the North America region is 7%. Thus, there still is an untapped market in the U.S. that contraceptive manufacturers can address. Furthermore, with no-cost coverage insurance policy for sterilization, growth for U.S. contraceptive drugs and devices market is restricted.

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/368

Statistics revealed by the United Nations in 2015, mentions that sterilization is a dominant contraceptive method in regions such as North America. Intra-uterine devices (IUDs), vaginal rings, injectables, implants, combined oral contraceptives, and patches are some of the advanced contraceptive methods available in the market. Therefore, various strategies such as promotion through sales force, social media promotion, awareness campaigns, and sampling are adopted by companies marketing contraceptive drugs and devices in the U.S. Introduction of new male contraceptive products with high success rate are projected to shape the course of growth of the U.S. contraceptive drugs and devices market in the near future.

The global U.S. contraceptive drugs and devices market was valued at US$ 6,785.9 million in 2016 and is expected to expand at a CAGR of 5.6% during the forecast period (2016 – 2024)

Oral pills resulting in volatility in the U.S. contraceptive drugs and devices market

Private companies have high interest in selling contraceptive pills as they generate continuous revenues for them compared to one-time long acting contraceptive methods. Furthermore, patent expiration is projected to lead to a barrage of generics entering into the market, further reducing overall average cost of drugs and in turn market revenue. Global generic pharmaceutical companies such as Teva Pharmaceuticals, Lupin Laboratories and Cipla Limited are at pace to launch their generic versions. Emergency contraceptive pills are among the most popular category of pills owing to extensive promotion activities to market these products.

Browse Research Report At: https://www.coherentmarketinsights.com/market-insight/us-contraceptives-drugs-and-devices-market-368

Favorable reimbursement scenario pushing uptake of contraceptives among low and middle-income population

The U.S. Affordable Care Act emphasizes on complete insurance coverage for long-acting reversible contraceptives (LARC). However, market players are interested in sustainable revenue generating oral pills. This public-private interest disparity impacts cost and product availability in different sections of the society.

Furthermore, the State announced insurance coverage of health and reproductive products to continue without any co-pays, co-insurance or deductibles. In addition to this, the new policy would also cover all medically essential abortion services for the U.S. population. This is a much anticipated relief for the general population in the U.S., where around 45% of all pregnancies reported are unintended (CDC, 2009-2013 study data).

Insurance coverage for devices also varies from state to state in the U.S. Few states have low Medicaid reimbursement rates than the cost of the device, while few states provide reimbursement only to those women who have been prescribed such devices. For instance, in California, dispensing of injectable contraceptives is only allowed by clinics, while Alabama, Idaho, and South California do not cover emergency contraceptive pills as part of the Medicaid programs in their respective states. Many such limitations in Medicaid coverage creates disparity in demand for certain contraceptives across regions in the U.S. Efforts to standardize the rule all over the country is expected to benefit the population at large and the overall U.S. contraceptive drugs and devices market.

Preference for modern contraceptive methods

Higher success rate and availability of reimbursement is encouraging women to opt for these methods over contraceptive pills. With increasing consumer awareness and rising accessibility to modern contraceptives methods, demand for these products is expected to increase during the forecast period. As per the United Nation’s 2015 report, 9 out of 10 married or in-union women opt for modern contraceptive methods. Furthermore, gynecologists and sexologists are recommending use of long-acting reversible contraceptives for couples who do not intend to have a child in near future, owing to their high affectivity compared to conventional contraceptives such as oral hormonal pills.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release U.S. Contraceptives Drugs And Devices Market, By Product Type - Insights, Opportunity Analysis, and Industry Forecast till 2024 here

News-ID: 773150 • Views:

More Releases for Contraceptive

Contraceptive Rings Market Segmentation By product type Etonogestrel/Ethinyl est …
Contraceptive rings are smooth, flexible round shaped plastic rings which are meant to insert into vagina to on first day woman’s menstrual cycle to prevent possible pregnancy. When contraceptive rings are placed into the vagina it releases two hormones named estrogen and progestogen which are similar to natural hormones released by the body and which are also used in the contraceptive pills. Contraceptive rings release continuous dose of these hormones
Contraceptive Pills
Oral contraceptive pills is a kind of female hormonal anti-conception medication technique that is used for avoiding pregnancy. Contraceptive drugs are used to prevent the unwanted pregnancy by blocking the normal process of ovulations or by altering the process which support the fertilization of egg. The prevalence of women with unmet contraception needs was accounted at 214 million in 2018 by WHO. Further, as indicated by, United Nations,
Contraceptive Rings Market Segmentation By product type Etonogestrel/Ethinyl est …
Contraceptive rings are smooth, flexible round shaped plastic rings which are meant to insert into vagina to on first day woman’s menstrual cycle to prevent possible pregnancy. When contraceptive rings are placed into the vagina it releases two hormones named estrogen and progestogen which are similar to natural hormones released by the body and which are also used in the contraceptive pills. Contraceptive rings release continuous dose of these hormones
U.S. Contraceptives Drugs And Devices Market, By Product Type (Contraceptive Dru …
Contraceptive Drugs and Devices – Choice to Conceive, Not Concede As per stats released by Guttmacher Institute, there were around 61 million women in the U.S. in the childbearing age group (15-44 years) in 2014. Around 10% of these women do not use any contraceptive method. The UN estimates (2015) that unmet need for contraceptives in the North America region is 7%. Thus, there still is an untapped market in the
Global Contraceptives Drugs And Devices Market, By Product Type (Contraceptive D …
Contraceptives are birth spacing products that aid in avoiding unwanted/ unplanned pregnancy. There are five widely used contraceptive methods namely barrier method, hormonal method, emergency contraception, intrauterine method, and sterilization. Women can opt for wide range of contraceptive options such as vaginal rings, diaphragms, female condoms, oral pills, and intra-uterine devices (IUD). Selecting the most appropriate method is critical to avoid undesired side effects. The use of contraceptives can avoid
Oral Contraceptive Pills Market: Snapshot
Teva Pharmaceutical is one of the leading companies in the combination oral contraceptive pills segment and is followed by Allergan (Actavis) plc. Local manufacturers such as Alkem, Taj Pharma, and Zydus Alidec on the other hand, held a majority of the market for ormeloxifene and mifepristone. Transparency Market Research has observed that almost all manufacturers offer combination oral contraceptive pills owing to the fact that they are more efficient, cost